Edgewise Therapeutics (EWTX) shares were down more than 3% early Thursday after the company reported a Q1 net loss of $0.43 per diluted share, widening from $0.42 the preceding quarter.
Analysts polled by FactSet expected a GAAP loss of $0.43 per share.
No revenue was reported for the quarter ended March 31.
Price: 14.06, Change: -0.46, Percent Change: -3.17
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.